On September 27, 2024, at 3:15 PM EST, BeyondSpring (BYSI, Financial) experienced significant stock movement, with its price soaring by 6.83%. As of this report, BYSI's stock trades at $2.19 per share, with a trading volume of 22,928 shares and a turnover rate of 0.06%. The stock's volatility reached 6.34%.
Recent financial reports indicate that BYSI generated a revenue of $1,000,000 but posted a net loss of $7.26 million, resulting in an earnings per share (EPS) of -$0.19. The stock's price-to-earnings (P/E) ratio stands at -5.25. Currently, no institutional ratings are available for this stock.
In the broader biotechnology sector, which faced an overall decline of 1.10%, some stocks showed significant gains. These include Nls Pharmaceutics Ltd C/Wts 02/02/2026, Onconetix, Inc., and Cue Biopharma, Inc. Active stocks in this sector include Onconetix, Inc., Seelos Therapeutics, Inc., and Aditxt, Inc., with turnover rates of 4469.74%, 279.48%, and 155.72%, respectively. Stocks with notable volatility include Pasithea Therapeutics Corp C/Wts 12/08/2026, Estrella Immunopharma Inc C/Wts 29/09/2028, and Estrella Immunopharma, Inc., with volatilities of 167.75%, 69.81%, and 65.94%, respectively.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focusing on cancer therapy development and immuno-oncology drugs. It operates primarily through two segments: the Plinabulin pipeline and the TPD platform.
